The global rivalry for top scientific talent in biopharma R&D is about to get a lot hotter
Tony Ho was a key player in AstraZeneca’s oncology R&D group, helping lead successful Phase III studies for Lynparza and Imfinzi — two of its top new drugs. But the senior vice president has moved on to another company now, AstraZeneca confirms for me, underscoring a significant migration of top R&D talent that will soon see growing competition among the top players for the best scientists in drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.